The effects of angiotensin II receptor antagonist (candesartan) on rat renal vascular resistance

The effects of angiotensin II receptor antagonist (candesartan) on rat renal vascular resistance

The present study aimed to investigate the action of angiotensin II (AII) on renal perfusion pressure and renal vascular resistance using noncompetitive AT1-receptor antagonist (candesartan or CV 11974). Experiments were performed in isolated kidney of adult male Wistar rats. Kreb's Henseleit s...

Full description

Bibliographic Details
Main Authors:	Supatraviwat, J, Hiranphun, P., Hiranyachattada, S.
Format:	Article
Language:	English
Published:	Prince of Songkla University 2004-05-01
Series:	Songklanakarin Journal of Science and Technology (SJST)
Subjects:	AT1- receptor antagonist candesartan (CV 11974) renal perfusion pressure renal vascular resistance
Online Access:	http://www.sjst.psu.ac.th/journal/26-4pdf/06-rat.pdf

Similar Items

Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity
by: Wen-Yu Lin, et al.
Published: (2022-05-01)

Differential clinical profile of candesartan compared to other angiotensin receptor blockers
by: Zimlichman R
Published: (2011-12-01)

Cerebroprotective effects of angiotensin II receptor blockers: candesartan focus
by: O. D. Ostroumova, et al.
Published: (2018-09-01)

The Effect of Candesartan Alone and Its Combination With Estrogen on Post-traumatic Brain Injury Outcomes in Female Rats
by: Mojdeh Hajmohammadi, et al.
Published: (2019-12-01)

Candesartan Normalizes Changes in Retinal Blood Flow and p22phox in the Diabetic Rat Retina
by: Randa S. Eshaq, et al.
Published: (2021-03-01)

Candesartan in treating hypertension
by: L O Minushkina
Published: (2014-03-01)

Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study
by: Nakayama Tomohiro, et al.
Published: (2011-08-01)

EFFECT OF CANDESARTAN ON PARAMETERS OFDAILYBLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEYDISEASE ON HEMODIALYSIS
by: V. A. Vizir, et al.
Published: (2017-12-01)

The comparison between combination of candesartan-amlodipine and candesartan-furosemide on blood pressure in hypertensive patients with chronic kidney disease
by: Dian Ayu Juwita, et al.
Published: (2022-07-01)

Candesartan in the prevention of cardiovascular catastrophes: emphasis on the pre-vention of stroke
by: Oksana Mikhaylovna Drapkina, et al.
Published: (2009-12-01)

The benefits of candesartan usage in the treatment of arterial hypertension
by: O D Ostroumova, et al.
Published: (2014-06-01)

Effects of combination of AT1-antagonist candesartan cilexetil and ASE-inhibitors in patients with congestive heart failure
by: Gašanin Edis, et al.
Published: (2013-01-01)

Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells
by: YING YU, et al.
Published: (2019-04-01)

CANDESARTAN IN CARDIOLOGY PRACTICE
by: N. A. Dzhaiani
Published: (2017-12-01)

ANTIDIURETIC EFFECTS OF THE ENDOTHELIN RECEPTOR ANTAGONIST AVOSENTAN
by: Ovidiu Constantin Baltatu, et al.
Published: (2012-04-01)

Mas receptor antagonist (A799) alters the renal hemodynamics responses to angiotensin II administration after renal moderate ischemia/reperfusion in rats: gender related differences
by: Maryam Maleki, et al.
Published: (2019-01-01)

Angiotensin II receptor blockers in the treatment of arterial hypertension in patients with concomitant pathology: focus on candesartan
by: D I Trukhan
Published: (2014-09-01)

No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects
by: Kim JR, et al.
Published: (2018-08-01)

Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer
by: Meredith Mihalopoulos, et al.
Published: (2020-08-01)

Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure
by: Sakamoto Masaya, et al.
Published: (2012-10-01)

Cost Effectiveness Kombinasi Antihipertensi Candesartan-Bisoprolol dan Candesartan-Amlodipin Pada Pasien Rawat Jalan Penderita Hipertensi
by: Eny Nurhikma, et al.
Published: (2019-12-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
by: Dong-Lim Kim, et al.
Published: (2023-02-01)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
by: Omar Y. Mady, et al.
Published: (2021-08-01)

Evaluation of the effectiveness of candesartan, diltiazem, or their combination on normo-, micro- and macroalbuminuria in type 2 diabetic patients
by: Jawad H. Ahmed, et al.
Published: (2013-12-01)

Intoxication with massive doses of amlodipine and candesartan requiring venoarterial extracorporeal membrane oxygenation
by: Minagawa Yusuke, et al.
Published: (2023-01-01)

POSSIBILITY OF ANGIOTENSIN RECEPTOR BLOCKERS IN OPTIMIZING OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN PATIENTS AFTER STROK
by: Z M. Sizova
Published: (2015-09-01)

A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension
by: Di Zhao, et al.
Published: (2019-01-01)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
by: Lanlan Xu, et al.
Published: (2021-09-01)

THE EFFECT OF CANDESARTAN PRE-STROKE USE ON THE FUNCTIONAL OUTCOME OF POST ISCHEMIC STROKE PATIENTS IN BETHESDA HOSPITAL YOGYAKARTA
by: Lise Insani Gulo, et al.
Published: (2018-05-01)

Blockade of Central Angiotensin II AT1 Receptor Protects the Brain from Ischemia/Reperfusion Injury in Normotensive Rats
by: Hamdolah Panahpour, et al.
Published: (2014-10-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND PROTEINURIA
by: Tanja Kök, et al.
Published: (2002-03-01)

Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
by: Marie‐Pierre Dubé, et al.
Published: (2022-10-01)

Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine
by: K Sharun, et al.
Published: (2021-11-01)

Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation
by: Josef Jampilek, et al.
Published: (2012-11-01)

Arterial hypertension, cardiovascular remodeling and plasma level of osteopontin in patients with end-stage kidney disease on hemodialysis
by: V. A. Vizir, et al.
Published: (2014-12-01)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
by: Andrés Figueroa-Campos, et al.
Published: (2020-07-01)

Genetic variants of GRK4 influence circadian rhythm of blood pressure and response to candesartan in hypertensive patients
by: Nian Cao, et al.
Published: (2021-10-01)

CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC COR PULMONALE BY ANGIOTENSIN II RECEPTORS ANTAGONISTS
by: V. S. Zadionchenko, et al.
Published: (2015-12-01)

Response surface based optimization of system variables for liquid chromatographic analysis of candesartan cilexetil
by: Jagdish V. Manwar, et al.
Published: (2017-01-01)

Renal blood flow and vascular resistance responses to angiotensin II in irreversible and reversible unilateral ureteral obstruction rats; the role of angiotensin II type 1 & 2 receptors
by: Jalal Hassanshahi, et al.
Published: (2018-04-01)